Biodexa Pharmaceuticals plc 424B Filings

Biodexa Pharmaceuticals plc (BDRX) filed a prospectus supplement to its Form F‑1 registration statement covering the resale by a selling shareholder of up to 29,926,150 ordinary shares represented by 598,523 American Depositary Shares (ADSs). The supplement incorporates a Form 6‑K describing a warrant inducement with an accredited holder of the company’s Series M, N and O warrants. The holder is exercising all of its Existing Warrants for an aggregate 2,204,218 ADSs at an exercise price of $1.05 per ADS, and Biodexa expects gross proceeds of about $2.3 million before fees. In return, the holder receives new unregistered Series P warrants to purchase up to 4,408,436 ADSs, also at $1.05 per ADS, exercisable immediately for five years, with standard anti‑dilution adjustments but no price protection. The new warrants are subject to a Beneficial Ownership Limitation of 4.99% or 9.99% and can be exercised on a cashless basis if resale registration is not effective after six months. Biodexa agrees to file a resale registration statement for the ADSs underlying the Series P warrants within 15 days of the agreement and to use commercially reasonable efforts to have it declared effective within 45 days of closing, and will pay Maxim Group LLC an 8% cash fee on the gross proceeds.

Biodexa Pharmaceuticals PLC (BDRX) updated its Form F-1 resale registration to cover up to 127,754,750 ordinary shares represented by 2,555,095 ADSs, issuable upon exercise of previously issued pre-funded, Series M, Series N and Series O warrants by selling shareholders.

Separately, Biodexa entered into a warrant inducement agreement with an accredited holder, reducing the exercise price of its outstanding Series M, N and O warrants being exercised to $1.05 per ADS. The holder is exercising 2,204,218 ADSs, and Biodexa expects to receive approximately $2.3 million in gross proceeds. In consideration, the company will issue Series P warrants for up to 4,408,436 ADSs, exercisable immediately at $1.05 for five years, with anti-dilution adjustments and a beneficial ownership limitation. Biodexa agreed to file a resale registration statement for the ADSs underlying the Series P warrants and pay an 8.0% cash fee on gross proceeds to Maxim Group LLC as warrant solicitation agent.

Biodexa Pharmaceuticals PLC (BDRX) filed a prospectus supplement updating its Form F-1 resale registration for up to 170,150 ordinary shares represented by 3,403 ADSs, to include a recent warrant transaction.

The company entered a warrant inducement agreement with an accredited holder, who agreed to exercise 2,204,218 ADSs of existing Series M, N and O warrants at $1.05 per ADS for anticipated gross proceeds of about $2.3 million, before fees and expenses. In return, the holder will receive new Series P warrants to purchase up to 4,408,436 ADSs at $1.05, exercisable immediately for five years, with customary anti-dilution adjustments and a 4.99% or 9.99% Beneficial Ownership Limitation. Biodexa agreed to file a resale registration statement for the ADSs underlying the new warrants within 15 days and to use commercially reasonable efforts to make it effective within 45 days of closing, with liquidated damages if registration or legend removal is delayed. Maxim Group LLC will receive an 8.0% cash fee on the gross proceeds as warrant solicitation agent.

Biodexa Pharmaceuticals PLC (BDRX) filed a prospectus supplement and Form 6-K describing ongoing registered warrant shares and a new warrant-inducement financing. The registration statement continues to cover up to 97,800 ADSs from pre-funded warrants, 1,219,512 ADSs from Series L warrants, and 30,487 ADSs from placement agent warrants.

Separately, an accredited holder agreed on September 14, 2026 to exercise 2,204,218 ADSs of existing Series M, N and O warrants at $1.05 per ADS, which is expected to provide Biodexa with approximately $2.3 million in gross cash proceeds. In return, the holder will receive new Series P warrants to purchase up to 4,408,436 ADSs at $1.05, exercisable immediately for five years, subject to anti-dilution adjustments and beneficial ownership limits. Biodexa will pay Maxim Group LLC an 8.0% cash fee on gross proceeds and has committed to file a resale registration statement for the ADSs underlying the Series P warrants.

Biodexa Pharmaceuticals PLC (BDRX) filed Prospectus Supplement No. 4 to its Form F-1, which continues to cover the resale by selling shareholders of 17,150 ordinary shares represented by 343 American Depositary Shares (ADSs), and incorporates new disclosure on a warrant inducement transaction.

On September 14, 2026, Biodexa entered into an agreement with an accredited holder of its Series M, N and O warrants to reduce the exercise price of the exercised warrants to $1.05 per ADS. The holder is exercising all of these warrants, resulting in the issuance of 2,204,218 ADSs, and Biodexa expects to receive approximately $2.3 million in gross proceeds, before fees and expenses, with Maxim Group LLC earning an 8.0% cash fee on such proceeds.

In consideration, the investor will receive new unregistered Series P warrants to purchase up to 4,408,436 ADSs at an exercise price of $1.05, which are immediately exercisable and have a five‑year term, subject to standard anti‑dilution adjustments and a Beneficial Ownership Limitation of 4.99% or 9.99%. Biodexa agreed to file a resale registration statement for the ADSs underlying the Series P warrants within 15 days of the agreement and to use commercially reasonable efforts to have it declared effective within 45 days of closing.

Biodexa Pharmaceuticals PLC (BDRX) filed a prospectus supplement updating a resale registration for up to 94,300 ordinary shares represented by 1,886 ADSs, which may be sold from time to time by selling shareholders. This does not involve the company issuing new securities for its own account.

Separately, Biodexa entered into a warrant inducement transaction with an accredited holder of its Series M, N and O warrants. The holder is exercising all existing warrants to purchase an aggregate of 2,204,218 ADSs at an exercise price of $1.05 per ADS, providing expected gross proceeds of approximately $2.3 million, before an 8.0% cash fee to Maxim Group LLC and other expenses. In return, the investor receives new unregistered Series P warrants to purchase up to 4,408,436 ADSs at $1.05, exercisable immediately for five years, with anti-dilution and beneficial ownership limits of 4.99% or 9.99%. Biodexa agreed to register the resale of ADSs underlying the new warrants shortly after closing and may owe liquidated damages if it does not meet the agreed registration and legend-removal timelines.

Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement for the resale by selling shareholders of up to 127,754,750 ordinary shares, represented by 2,555,095 ADSs, issuable upon exercise of outstanding warrants, and reported unaudited interim results for the six months ended June 30, 2026. The company advanced its pipeline, including the registrational Phase 3 “Serenta” trial of eRapa in Familial Adenomatous Polyposis, an investigator-sponsored Phase 2 trial in non-muscle invasive bladder cancer, and in-licensed MTX240, a novel “molecular glue” for GIST. For 1H26, it recorded no revenue, a reduced net loss of £1.84 million and higher R&D investment of £2.92 million, while cash fell to £3.23 million with a net operating cash outflow of £4.61 million. Despite a July 2026 fundraise of $3.5 million and access to an undrawn $26.08 million equity line, management discloses a material uncertainty about going concern, expecting the need for additional financing during Q4 2026 and noting potential risks to continued Nasdaq listing if proposed minimum market value rules take effect.

Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement covering the resale by selling shareholders of up to 17,150 ordinary shares, represented by 343 American Depositary Shares, and concurrently reported unaudited results for the six months ended June 30, 2026.

For 1H26, Biodexa recorded a net loss of £1.84 million, an improvement from £3.81 million in 1H25, on R&D costs of £2.92 million (up 75%) and administrative costs of £1.74 million (down 27%). Finance income was £2.47 million, mainly from a gain on an equity‑settled derivative liability linked to a lower share price. Cash used in operating activities was £4.61 million, leaving £3.23 million of cash at June 30, 2026.

The company advanced its GI cancer pipeline, including a registrational Phase 3 eRapa trial in FAP with 92 of 168 subjects enrolled and in‑licensed MTX240 for GIST. On July 1, 2026 it raised $3.5 million gross via ADS and warrant financing, and has $26.08 million remaining under a $35 million Equity Line of Credit. Directors nonetheless highlight a material uncertainty about going concern, as additional financing is expected to be required during Q4 2026 amid challenging micro‑cap biotech markets and potential Nasdaq minimum market value pressures.

Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement covering the resale by selling shareholders of up to 94,300 ordinary shares, represented by 1,886 American Depositary Shares, and concurrently furnished interim results for the six months ended June 30, 2026.

The company reported no revenue, a loss from operations of £4.21 million and a net loss of £1.84 million, improved from a £3.81 million loss a year earlier, helped by £2.47 million of finance income largely from a gain on a derivative liability. R&D expenses rose to £2.92 million (vs. £1.67 million), mainly from the Phase 3 eRapa FAP trial and new MTX240 GIST program, while administrative costs fell to £1.74 million (vs. £2.38 million).

Cash used in operations was £4.61 million, with total cash decreasing to £3.23 million at June 30, 2026. A July 1, 2026 financing raised $3.5 million gross via ADSs and pre-funded warrants, and the company retains $26.08 million undrawn under a $35 million Equity Line of Credit. The board highlights a material uncertainty related to going concern, noting that additional financing is expected to be required during Q4 2026.

Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement covering the resale by selling shareholders of up to 170,150 ordinary shares represented by 3,403 ADSs, and furnished unaudited results for the six months ended June 30, 2026.

Revenue was £0, while R&D costs rose 75% to £2.92 million, reflecting higher spend on the Phase 3 Serenta trial of eRapa in Familial Adenomatous Polyposis and initiation of MTX240 for GIST. Administrative costs fell 27% to £1.74 million, helped by foreign exchange gains and lower professional fees. The net loss narrowed to £1.84 million from £3.81 million, supported by £2.47 million of finance income driven by a gain on an equity‑settled derivative liability.

Cash and cash equivalents were £3.23 million at June 30, 2026, after £4.61 million of operating cash outflow. A July 1, 2026 financing raised $3.5 million gross, and $26.08 million remains available under a $35 million Equity Line of Credit. Even so, the company discloses a material uncertainty about going concern, with forecasts indicating a need for further financing during Q4 2026, and notes potential risk from Nasdaq’s proposed $5 million minimum market value requirement. Clinically, eRapa’s Phase 3 FAP trial has recruited 92 of 168 subjects and MTX240 was in‑licensed as a new molecular glue program for GIST.

Biodexa Pharmaceuticals plc (BDRX) filed a prospectus supplement covering the resale by existing holders of 10,950 ordinary shares represented by 219 American Depositary Shares (ADSs), and at the same time furnished unaudited interim results for the six months ended June 30, 2026.

The company is advancing its oncology portfolio: the registrational Phase 3 “Serenta” trial of eRapa in Familial Adenomatous Polyposis has enrolled 92 of 168 planned subjects across the US and Europe, with Canadian sites expected in late 2026, and a Phase 2 trial in non-muscle invasive bladder cancer is fully enrolled with support from a $3.0 million grant. Biodexa also in-licensed MTX240, a novel “molecular glue” for treatment‑resistant GIST, and continues an investigator‑initiated Phase 2a trial of tolimidone in Type 1 diabetes. Financially, revenue remained £Nil, R&D spending rose 75% to £2.92 million, administrative costs fell 27%, and the net loss narrowed to £1.84 million from £3.81 million, aided by a £2.47 million finance gain from a derivative liability revaluation. Cash decreased to £3.23 million, with operating cash outflow of £4.61 million, partly mitigated by $3.5 million gross proceeds from a July 1, 2026 equity financing and access to an undrawn $26.08 million equity line, yet management discloses a material uncertainty about going concern given the need for additional funding in Q4 2026.

Biodexa Pharmaceuticals Plc (BDRX) has filed a prospectus supplement covering the resale of up to 29,926,150 ordinary shares represented by 598,523 ADSs by an existing selling shareholder and simultaneously reports unaudited results for the six months ended June 30, 2026. The supplement primarily incorporates the attached Form 6-K, including the Chief Executive’s Review, 1H26 Financial Review and interim financial statements, into existing registration statements. In 1H26, Biodexa advanced its registrational Phase 3 “Serenta” trial of eRapa in Familial Adenomatous Polyposis, reaching 92 subjects enrolled across US and European sites, in-licensed MTX240 for GIST from Otsuka, and continued an investigator-led Phase 2 NMIBC trial and a Phase 2a tolimidone study in Type 1 diabetes. Financially, R&D spending rose 75% to £2.92 million as the pipeline expanded, while the net loss narrowed to £1.84 million helped by a £2.47 million finance gain from a fall in the share-price-linked derivative liability. Cash and cash equivalents declined to £3.23 million at June 30, 2026, with an additional $3.5 million gross raised on July 1, 2026, and £157.60 million of accumulated deficit; management explicitly highlights a material uncertainty about going concern given expected need for further financing in Q4 2026 despite access to an undrawn $26.08 million capacity under a $35 million Equity Line of Credit.

Biodexa Pharmaceuticals PLC (BDRX) filed a prospectus supplement updating its F-1 registration covering up to 97,800 ADS underlying pre-funded warrants, 1,219,512 ADS underlying Series L warrants, and 30,487 ADS underlying placement agent warrants, all issuable on a continuous basis. The supplement incorporates unaudited results for the six months ended June 30, 2026. Biodexa reported no revenue, a net loss of £1.84 million (improved from £3.81 million a year earlier), and R&D spending of £2.92 million, up 75%, driven mainly by the Phase 3 Serenta trial of eRapa and the new MTX240 GIST program. Cash and cash equivalents were £3.23 million at June 30, 2026, and a financing completed July 1, 2026 raised $3.5 million gross. The company highlights a material uncertainty regarding going concern, with forecasts indicating further financing needed during Q4 2026 and continued reliance on capital markets and a $35 million Equity Line of Credit, of which $26.08 million remained undrawn.

Biodexa Pharmaceuticals PLC filed a prospectus supplement covering the resale by selling shareholders of up to 94,300 ordinary shares, represented by 1,886 American Depositary Shares (ADS). The company’s ADSs trade on Nasdaq under the symbol BDRX, with a last reported closing price of $1.42 on August 3, 2026.

The company reports that shareholders approved all resolutions at a July 29, 2026 general meeting, including a one‑for‑10,000 reverse stock split of ordinary shares and authority to allot up to £25,000,000 for future share issuances through the annual general meeting in 2029. As of July 30, 2026, the ADS ratio changes from 1 ADS per 500,000 ordinary shares to 1 ADS per 50 ordinary shares, with no change in proportional ownership for holders. New Articles of Association reflecting these changes were approved and adopted.

Biodexa Pharmaceuticals PLC filed a prospectus supplement for the resale by existing selling shareholders of up to 170,150 Ordinary Shares, represented by 3,403 American Depositary Shares (ADS). The ADSs trade on the Nasdaq Capital Market under the symbol BDRX, with a last reported closing price of $1.42 on August 3, 2026.

The attached Form 6-K reports that shareholders at the July 29, 2026 general meeting approved all four resolutions, including a one‑for‑10,000 reverse stock split of Ordinary Shares and authority to allot up to £25,000,000 of share capital through the annual general meeting in 2029. The reverse split is expected to be effective July 30, 2026. Concurrently, the ADS ratio will change from one ADS per 500,000 Ordinary Shares to one ADS per 50 Ordinary Shares, structured so that ADSs themselves are not reverse split and proportional ownership for Ordinary Share and ADS holders remains unchanged. Shareholders also approved and adopted new Articles of Association, which, among other matters, codify governance, director powers, borrowing limits, and share mechanics.

Biodexa Pharmaceuticals PLC filed a prospectus supplement updating a resale registration covering up to 29,926,150 Ordinary Shares, represented by 598,523 American Depositary Shares (ADS). The supplement incorporates a Form 6-K describing shareholder approvals from the July 29, 2026 general meeting.

Shareholders approved a one-for-10,000 reverse stock split of Ordinary Shares, expected to be effective as of July 30, 2026, and authorized the allotment of up to £25,000,000 for future share issuances through the 2029 annual general meeting. They also approved new Articles of Association reflecting these changes.

Concurrently with the reverse split, the ADS ratio will change by a factor of 10,000, from one ADS per 500,000 Ordinary Shares to one ADS per 50 Ordinary Shares. The company states this ADS ratio change will not itself constitute a reverse split of the ADSs, and proportional ownership for holders of Ordinary Shares and ADSs will remain unchanged. The last reported closing price of the ADSs on NASDAQ on August 3, 2026 was $1.42.

Biodexa Pharmaceuticals PLC updates its prospectus for a previously completed “best efforts” offering by incorporating a new Form 6-K. The registration covers up to 97,800 ADSs representing 4,890,000 ordinary shares underlying pre-funded warrants, up to 1,219,512 ADSs representing 60,975,600 ordinary shares underlying Series L warrants, and up to 30,487 ADSs representing 1,524,350 ordinary shares underlying placement agent warrants, issuable on a continuous basis.

Shareholders approved all resolutions at the July 29, 2026 general meeting, including a one-for-10,000 reverse stock split of ordinary shares, authority to allot up to £25,000,000 for future share issuances through the 2029 AGM, and adoption of new articles of association. Concurrently, the ADS ratio will change by a factor of 10,000 to one ADS per 50 ordinary shares, which is stated not to alter proportional ownership. Biodexa’s ADSs trade on Nasdaq under “BDRX,” with a last reported closing price of $1.42 on August 3, 2026.

Biodexa Pharmaceuticals PLC is updating a resale registration covering up to 10,950 ordinary shares, represented by 219 American Depositary Shares (ADS), by incorporating new information from a July 2026 Form 6-K.

Shareholders approved a one-for-10,000 reverse stock split of the company’s ordinary shares, expected to be effective as of July 30, 2026, along with authority to allot up to £25,000,000 of shares for future issuances through the 2029 annual general meeting and the adoption of new Articles of Association. Concurrent with the reverse split, the ADS ratio will change from 1 ADS per 500,000 ordinary shares to 1 ADS per 50 ordinary shares, which the company states will not itself constitute a reverse split of the ADSs or alter proportional ownership of ordinary or ADS holders. The company’s ADSs trade on Nasdaq under the symbol BDRX, with a last reported closing price of $1.42 on August 3, 2026.

Biodexa Pharmaceuticals PLC filed a prospectus supplement for the resale by existing selling shareholders of up to 17,150 ordinary shares, represented by 343 American Depositary Shares (ADS). The ADSs trade on NASDAQ under the symbol BDRX, with a last reported closing price of $1.42 on August 3, 2026.

The company reports that shareholders approved a one-for-10,000 reverse stock split of the ordinary shares and an authority to allot up to £25,000,000 of share capital for future issuances through the 2029 annual general meeting. Concurrently with the reverse split, the ADS ratio will change from 1 ADS per 500,000 ordinary shares to 1 ADS per 50 ordinary shares; this change is stated not to constitute a reverse split of the ADSs and not to alter proportional ownership for holders of ordinary shares or ADSs.

Biodexa Pharmaceuticals PLC is registering the resale by a selling shareholder of up to 127,754,750 Ordinary Shares represented by 2,555,095 American Depositary Shares (each ADS equals 50 Ordinary Shares), all issuable upon exercise of pre-funded and Series M, N and O warrants. The company will not receive proceeds from these resales but will receive cash only upon warrant exercises. Ordinary Shares outstanding were 51,453,281 before this registration and would be 179,208,031 if all warrants are exercised.

Biodexa is a clinical-stage biopharmaceutical company developing eRapa for FAP and NMIBC, MTX240 for GIST, and tolimidone for type 1 diabetes, while de‑prioritizing MTX110 and legacy delivery platforms. Recent financings include a July 2026 registered direct offering (~$0.8 million), a private placement (~$1.0 million) and a warrant inducement (~$1.7 million). A one‑for‑10,000 reverse split and multiple ADS ratio changes were completed to maintain NASDAQ listing. As of December 31, 2025, cash was £8,534k (pro forma £10,630k) and total equity was £11,405k (pro forma £13,501k).

Biodexa Pharmaceuticals PLC filed a Prospectus Supplement to its Form F-1 and a Form 6-K describing a set of securities transactions. The supplement covers the resale registration of 299,261,500,000 ordinary shares, represented by 598,523 ADSs, and the Company disclosed Offerings consisting of a Registered Direct Offering, concurrent private placements and a warrant inducement to raise proceeds.

The Registered Offering includes the sale of 82,809 ADSs at $2.85 each and 200,143 Registered Pre-Funded Warrants at $2.8499 each (each pre-funded warrant exercisable for one ADS at $0.0001). The Company also agreed to issue multiple series of unregistered warrants (Series M, N and O) contingent on shareholder approval. Aggregate gross proceeds from the Offerings and the Warrant Inducement are stated as approximately $3.54 million. The Prospectus Supplement incorporates a Form 6-K and a press release dated June 30, 2026.

Biodexa Pharmaceuticals PLC amends its March 30, 2026 prospectus to incorporate a prospectus supplement registering for resale up to 943,000,000 ordinary shares (represented by 1,886 ADSs). The supplement incorporates a Form 6-K describing a set of concurrent financings: a registered direct offering of 82,809 ADSs and 200,143 registered pre-funded warrants, concurrent private placements of 350,877 unregistered pre-funded warrants and private warrants, and related inducement warrants, subject in several cases to shareholder approval. The transactions are expected to generate aggregate gross proceeds of approximately $3.54 million before fees and are arranged with a placement agent paid an 8.0% cash fee. The supplement and Form 6-K describe exercise prices, beneficial ownership limits (4.99% or 9.99% at investor option), registration rights and customary closing conditions.

Biodexa Pharmaceuticals PLC amends its prospectus to register 109,500,000 ordinary shares (represented by 219 ADSs) for resale by selling shareholders. This Prospectus Supplement incorporates a Form 6-K describing concurrent financing arrangements including a registered direct offering of 82,809 ADSs and 200,143 registered pre-funded warrants at prices of $2.85 and $2.8499, respectively.

The Form 6-K also describes private placements of additional pre-funded warrants and warrants (Series M, N and O) exercisable upon shareholder approval, a warrant inducement arrangement, and an expected aggregate gross proceed estimate of approximately $3.54 million. Shareholder approval is required for the issuance and exercise of the Series M/N/O warrants.

Biodexa Pharmaceuticals PLC amends its March 30, 2026 prospectus to register the resale of 1,701,500,000 ordinary shares represented by 3,403 ADSs.

The supplement also discloses a registered direct offering of 82,809 ADSs at $2.85 per ADS and sale of 200,143 registered pre-funded warrants at $2.8499, concurrent private placements of 350,877 unregistered pre-funded warrants and unregistered warrants (Series M/N/O) exercisable subject to shareholder approval. Aggregate gross proceeds from the described transactions are expected to be approximately $3.54 million, and certain warrants have an exercise price of $0.0001 (pre-funded) or $2.85 (Series M/N/O). Several issuances and exercises are conditioned on shareholder approval and the resale registration process.

Biodexa Pharmaceuticals PLC files a prospectus supplement and Form 6-K describing completed and follow-on offerings and related warrant arrangements.

The supplement registers up to 97,800 ADSs (representing 48,900,000,000 Ordinary Shares), 1,219,512 ADSs (representing 609,756,000,000 Ordinary Shares) and 30,487 ADSs (representing 15,243,500,000 Ordinary Shares) underlying various warrants. The company completed a “best efforts” offering and separately agreed a Registered Direct Offering and private placements providing aggregate expected gross proceeds of approximately $3.54 million, subject to closing and shareholder approval.

Biodexa Pharmaceuticals PLC amends its March 30, 2026 prospectus to cover the resale of 171,500,000 Ordinary Shares represented by 343 American Depositary Shares. The supplement incorporates a Form 6-K disclosing a series of concurrent financings: a registered direct offering, private placements of pre‑funded warrants and contingent warrants, and a warrant inducement.

The company agreed to sell 82,809 ADSs at $2.85 and 200,143 Registered Pre‑Funded Warrants at $2.8499, with additional unregistered pre‑funded warrants and exercisable warrants contingent on shareholder approval. Aggregate gross proceeds are expected to be approximately $3.54 million, subject to closing conditions.

Biodexa Pharmaceuticals PLC is conducting a primary offering of 82,809 American Depositary Shares, each representing 500,000 ordinary shares, at a price of $2.85 per Depositary Share and is issuing 200,143 pre-funded warrants in lieu of certain Depositary Shares.

The prospectus supplement describes a concurrent private placement of Series M warrants exercisable for 282,952 Depositary Shares, related warrant inducement and a second private placement, and states expected gross offering proceeds, placement agent fees and estimated net proceeds to the company.

Biodexa Pharmaceuticals PLC registered for resale an aggregate of 943,400,000 Ordinary Shares represented by 9,434 Depositary Shares, issuable upon exercise of Series G warrants. The prospectus states the company will not receive any proceeds from resale by the selling shareholders; net proceeds will go to those selling shareholders, although the company would receive proceeds if warrants are exercised for cash. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.

Biodexa Pharmaceuticals PLC is registering the issuance of up to 489,000 American Depositary Shares (each ADS = 100,000 Ordinary Shares) representing 48,900,000,000 Ordinary Shares issuable upon exercise of Pre-Funded Warrants, plus up to 6,097,562 ADS representing 609,756,200,000 Ordinary Shares issuable upon exercise of Series L Warrants, and up to 152,439 ADS representing 15,243,900,000 Ordinary Shares issuable upon exercise of Placement Agent Warrants.

The prospectus describes exercise prices (Pre-Funded Warrants at $0.0001 per Depositary Share; Series L and Placement Agent Warrants at $3.28 per Depositary Share), cash‑or‑cashless exercise mechanics, beneficial ownership limits (commonly 9.99% or 4.99%) and plan of distribution terms. It also states 324,156,808,922 Ordinary Shares outstanding as of March 12, 2026 and a pro forma total of 998,056,908,922 Ordinary Shares assuming full exercise of the referenced warrants.

Biodexa Pharmaceuticals PLC registers for resale 171,700,000 Ordinary Shares represented by 1,717 Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement. The prospectus states the Company will receive proceeds only if warrants are exercised for cash at an exercise price of $0.025 per share; otherwise all net proceeds will go to the selling shareholders. The Depositary Shares trade on NASDAQ under the symbol BDRX and each Depositary Share represents 100,000 Ordinary Shares. The prospectus discloses 324,156,808,922 Ordinary Shares outstanding as of March 12, 2026 and notes potential sales may occur in market, negotiated or brokered transactions.

Biodexa Pharmaceuticals PLC registers for resale 1,701,800,000 Ordinary Shares represented by 17,018 Depositary Shares, each Depositary Share representing 100,000 Ordinary Shares, for sale from time to time by identified selling shareholders.

The prospectus states the Company will receive no proceeds from resale by the selling shareholders, although the Company may receive proceeds if Series J warrants are exercised for cash; if all Series J warrants were exercised for cash in full, proceeds would be approximately $4.3 million. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 1, 2026.

Biodexa Pharmaceuticals PLC files a resale prospectus registering an aggregate of 109,800,000 Ordinary Shares, represented by 1,098 Depositary Shares, issuable upon exercise of Series D Warrants.

The prospectus states we will not receive proceeds from sales by the selling shareholders; proceeds will go to those sellers, though the company may receive proceeds if warrants are exercised for cash. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.

Biodexa Pharmaceuticals PLC registers for resale up to 299,261,540,000 Ordinary Shares represented by 2,992,615 Depositary Shares (ADS) held or issuable to C/M Capital Master Fund, LP under an equity line Purchase Agreement.

The shares are being registered for resale by the Selling Shareholder; Biodexa is not selling shares here and will not receive proceeds from resale, although Biodexa may receive up to $35.0 million in aggregate gross proceeds if it elects to sell Depositary Shares to the Selling Shareholder under the Purchase Agreement. Each Depositary Share represents 100,000 Ordinary Shares. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.

Biodexa Pharmaceuticals PLC is registering for resale up to 109,800,000 ordinary shares represented by 1,098 American Depositary Shares held by selling shareholders, and is updating investors via a prospectus supplement and attached Form 6-K.

The company also reports an exclusive license and collaboration agreement with Otsuka Pharmaceutical, granting Biodexa rights outside Japan to develop, manufacture and commercialize MTX240, a Phase 1-ready molecular glue therapeutic candidate initially aimed at treating gastrointestinal stromal tumors. Biodexa will handle development, manufacturing and commercialization in its licensed territory, with Otsuka eligible for an upfront payment, development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of certain sublicense income.

Biodexa Pharmaceuticals PLC filed a prospectus supplement covering the resale by existing shareholders of up to 171,700,000 ordinary shares, represented by 1,717 American Depositary Shares. The supplement incorporates a new report describing a strategic licensing transaction.

The company entered an exclusive collaboration with Otsuka Pharmaceutical, obtaining worldwide rights outside Japan to develop, manufacture and commercialize MTX240 (OPB-171775), a Phase 1-ready molecular glue for gastrointestinal stromal tumors. Otsuka receives an upfront payment, potential development and regulatory milestones, and tiered mid-single-digit royalties on net sales, with MTX240 protected by composition of matter patents extending through 2037.

Biodexa Pharmaceuticals PLC files a prospectus supplement covering the resale of up to 4,349,000,000 ordinary shares represented by 43,490 American Depositary Shares by existing shareholders. The supplement also incorporates a Form 6-K describing a new license and collaboration agreement.

Biodexa obtained an exclusive license from Otsuka Pharmaceutical to develop, manufacture and commercialize MTX240 (OPB-171775) for all human therapeutic uses outside Japan. MTX240 is a Phase 1-ready molecular glue candidate initially aimed at gastrointestinal stromal tumors, with an upfront payment, development and regulatory milestones, and tiered mid-single digit royalties on net sales, supported by patents extending through 2037.

Biodexa Pharmaceuticals PLC filed a prospectus supplement covering the resale of up to 2,846,100,000 ordinary shares represented by 24,861 American Depositary Shares. The supplement incorporates a Form 6-K describing an exclusive license and collaboration with Otsuka for MTX240, a Phase 1-ready molecular glue for gastrointestinal stromal tumours.

Biodexa receives exclusive rights to develop, manufacture and commercialize MTX240 outside Japan, while Otsuka retains Japanese rights. Otsuka receives an upfront payment, potential one-time development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of sublicense income. MTX240’s patents extend through 2037 and preclinical data suggest activity in tyrosine kinase inhibitor-resistant GIST models, aligning with Biodexa’s rare disease oncology strategy.

Biodexa Pharmaceuticals files a prospectus supplement to its existing Form F-1 to incorporate a new Form 6-K describing an exclusive license and collaboration with Otsuka Pharmaceutical for MTX240, a Phase 1-ready molecular glue therapeutic candidate initially aimed at treating gastrointestinal stromal tumors (GIST).

Under the agreement, Biodexa receives exclusive rights to develop, manufacture and commercialize MTX240 worldwide excluding Japan, while Otsuka retains Japanese rights. Biodexa made an upfront payment and Otsuka is entitled to one-time development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of any sublicense income.

The attached press release explains that MTX240 (OPB-171775) uses a molecular glue mechanism to induce apoptosis in GIST cells through a pathway independent of KIT signaling and has shown dose-dependent anti-tumor activity in tyrosine kinase inhibitor–resistant patient-derived xenograft models, targeting a population with significant unmet medical need.

Biodexa Pharmaceuticals PLC filed a prospectus supplement for the resale by a selling shareholder of up to 341,352,000,000 ordinary shares, represented by 3,413,520 American Depositary Shares. The supplement also incorporates a Form 6-K describing a new licensing deal.

The company entered into an exclusive, worldwide (excluding Japan) license and collaboration agreement with Otsuka Pharmaceutical for OPB-171775, a Phase 1-ready molecular glue therapeutic to be developed as MTX240 for gastrointestinal stromal tumors. Biodexa will handle development, manufacturing, and commercialization outside Japan, while Otsuka keeps Japanese rights.

Otsuka received an upfront payment and may receive one-time development and regulatory milestones, plus tiered mid-single-digit royalties on net sales and a share of any sublicense income. MTX240 is backed by composition-of-matter patents in major territories extending through 2037.

Biodexa Pharmaceuticals is registering 929,878,200,000 Ordinary Shares, in the form of American Depositary Shares (Depositary Shares), for a best-efforts public offering. The deal comprises 157,000 Units at $3.28 per Unit, each with one Depositary Share and two Series L Warrants, plus up to 2,891,781 Pre-Funded Units at $3.2799 each, with a Pre-Funded Warrant and two Series L Warrants. Each Series L Warrant is immediately exercisable at $3.28 for five years; each Pre-Funded Warrant is exercisable at $0.0001 per Depositary Share without expiry, subject to 4.99% or 9.99% beneficial ownership caps.

If all Units are sold, Biodexa estimates net proceeds of about $8.75 million, to be used to fund its development programs, working capital and general corporate purposes. Ordinary Shares outstanding are expected to rise from 68,178,708,922 to 83,878,708,922 after the offering, before any warrant exercises. The company highlights that this equity raise and potential future warrant exercises may significantly dilute existing holders and pressure the trading price.

Biodexa Pharmaceuticals PLC filed a prospectus supplement tied to a resale registration for up to 341,352,000,000 ordinary shares, represented by 3,413,520 American Depositary Shares. The company also describes a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including warrants with an exercise price of $3.28 per ADS. Net proceeds from this offering are expected to be about $8.75 million, to fund development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported unaudited cash and cash equivalents of £2.79 million and notes that, after the offering and before any warrant exercises, 83,878,708,922 ordinary shares will be outstanding.

Biodexa Pharmaceuticals PLC files a prospectus supplement covering the resale of up to 171,700,000 ordinary shares, represented by 1,717 American Depositary Shares (ADSs). Alongside this, the company has launched a best-efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including warrants. The offering is expected to generate approximately $8.75 million in net proceeds, which the company plans to use to fund its development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported cash and cash equivalents of £2.79 million, and assuming the offering closes with no warrant exercises, it will have 83,878,708,922 ordinary shares outstanding.

Biodexa Pharmaceuticals filed a prospectus supplement covering the resale by existing shareholders of up to 109,800,000 ordinary shares represented by 1,098 American Depositary Shares. The company also commenced a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including one ADS or pre-funded warrant plus two Series L warrants, at combined prices of $3.28 and $3.2799 per unit. Net proceeds from this offering are expected to be approximately $8.75 million to fund development programs, working capital and other general corporate purposes, with closing anticipated on or about December 19, 2025. As of September 30, 2025, cash and cash equivalents were £2.79 million, and after the offering the company expects to have 83,878,708,922 ordinary shares outstanding, assuming no warrant exercises.

Biodexa Pharmaceuticals PLC supplements its resale prospectus covering up to 4,349,000,000 ordinary shares, represented by 43,490 American Depositary Shares (ADSs), that may be sold from time to time by existing shareholders. Alongside this, the company has begun a best efforts public offering of 157,000 ADS units, each with one ADS and two Series L warrants, and 2,891,781 pre-funded units, each with a pre-funded warrant and two Series L warrants, at combined prices of $3.28 and $3.2799 per unit, respectively.

The offering is expected to generate approximately $8.75 million in net proceeds, which the company plans to use for development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported cash and cash equivalents of £2.79 million83,878,708,922 ordinary shares outstanding. New Series L and pre-funded warrants carry exercise caps at 4.99% or 9.99% beneficial ownership to limit concentration.

Biodexa Pharmaceuticals is registering for resale up to 2,846,100,000 ordinary shares, represented by 24,861 American Depositary Shares (ADSs), held by existing shareholders. Separately, the company has begun a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including ADSs or pre-funded warrants plus two Series L warrants. Unit pricing is $3.28 per ADS unit and $3.2799 per pre-funded unit, with Series L warrants exercisable at $3.28 for five years and pre-funded warrants at $0.0001 per ADS. Net proceeds from this primary offering are expected to be about $8.75 million, intended for development programs, working capital and general corporate purposes. As of September 30, 2025, the company reported £2.79 million in cash and cash equivalents and later settled a previously disclosed advisor fee dispute via a payment. Assuming the offering closes and no warrants are exercised, 83,878,708,922 ordinary shares will be outstanding.

Biodexa Pharmaceuticals PLC is registering 109,800,000 Ordinary Shares represented by 1,098 Depositary Shares for resale by holders of Series D warrants issued in a June 2023 private placement. The company is not selling any Depositary Shares in this offering and will not receive proceeds from shareholder resales, although it could receive up to $4.4 million if all Series D Warrants are exercised for cash.

Ordinary Shares outstanding were 61,952,308,922 as of November 1, 2025. Biodexa is a clinical-stage biopharmaceutical company focused on eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, and tolimidone for type 1 diabetes, while MTX110 for rare brain cancers has been de-prioritized. eRapa has FDA fast track designation and European orphan drug designation, with an ongoing Phase 3 FAP trial and Phase 2 NMIBC study.

As of September 30, 2025, Biodexa reported unaudited cash and cash equivalents of £2.79 million. The prospectus highlights that large-scale resale of shares could pressure the market price and that future issuances may dilute existing holders.

Biodexa Pharmaceuticals (BDRX) has filed a resale registration covering 171,700,000 Ordinary Shares represented by 1,717 American Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement. All sale proceeds for these shares will go to the selling shareholders; Biodexa would receive only any cash exercise proceeds at an exercise price of $0.025 per share.

Ordinary Shares outstanding were 61,952,308,922 as of November 1, 2025. Biodexa is a clinical-stage biopharmaceutical company focused on eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, and tolimidone for type 1 diabetes, with MTX110 for rare brain cancers de-prioritized due to resource constraints.

eRapa has fast track designation from the U.S. FDA and orphan drug designation in Europe for FAP, with a Phase 3 study underway and supported by a $3.0 million CPRIT grant. As of September 30, 2025, cash and cash equivalents were £2.79 million, highlighting the importance of external funding sources for ongoing development. The company does not expect to pay dividends in the foreseeable future.

Biodexa Pharmaceuticals PLC filed Prospectus Supplement No. 10 to its Form F-1, covering the resale by selling shareholders of up to 4,349,000,000 ordinary shares represented by 43,490 American Depositary Shares.

The supplement incorporates a Form 6-K announcing EMA approval of a Clinical Trial Application for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), permitting the study to proceed in Europe across sites in Denmark, Germany, the Netherlands and Spain, with Italy expected to be added. The company noted the first European patient is expected in 4Q 2025, and the U.S. arm enrolled its first patient in mid-August 2025. The registrational study plans to recruit 168 patients, randomized 2:1 (drug:placebo). Biodexa cited an addressable US–European market of $7 billion. The company’s ADS trade on Nasdaq as BDRX; the last reported close was $6.49 on October 31, 2025.

Biodexa Pharmaceuticals PLC filed a prospectus supplement for the resale of up to 341,352,000,000 ordinary shares represented by 3,413,520 American Depositary Shares under its effective F-1. The Depositary Shares trade on NASDAQ as BDRX; the last reported closing price was $6.49 on October 31, 2025.

The supplement also incorporates a Form 6-K announcing EMA approval of a Clinical Trial Application for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis, allowing the study to proceed in Europe at sites in Denmark, Germany, the Netherlands, and Spain, with Italy expected to be added. The U.S. arm enrolled its first patient in mid‑August 2025, and the company expects the first European patient in 4Q 2025. The Phase 3 study is randomized, double‑blind, and placebo‑controlled, with a planned enrollment of 168 patients randomized 2:1 drug to placebo.